# Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

> **NCT02793583** · PHASE2,PHASE3 · TERMINATED · sponsor: **TG Therapeutics, Inc.** · enrollment: 710 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma
- Small Lymphocytic Lymphoma

## Interventions

- **BIOLOGICAL:** Ublituximab
- **DRUG:** Umbralisib
- **BIOLOGICAL:** Bendamustine

## Key facts

- **NCT ID:** NCT02793583
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-25
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-07-04
- **Target enrollment:** 710 (ACTUAL)
- **Why stopped:** Strategic/Business Decision
- **Last updated:** 2022-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02793583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02793583, "Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02793583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*